Clinical trial
Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the…
NCT00214955 · Cephalon, Industry · Completed
Key facts
| NCT number | NCT00214955 |
|---|---|
| Title | Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain |
| Official title | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Neuropathic Pain |
| Lead sponsor | Cephalon, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Neuropathic Pain |
| Intervention type | Drug |
| Interventions | ORAVESCENT Fentanyl Citrate |
| Enrollment | 120 |
| Start date | Sep 1, 2005 |
| Primary completion | May 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | May 9, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: